Catalyst Event

Celltrion Inc (068270) · Other

From Akros K-Manufacturing 50 Index (AKMNF50)

4/30/2026, 12:00:00 AM

OtherSentiment: Positive

Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.

Korean Translation

셀트리온, 2026년 4월 30일 유방암 치료용 바이오시밀러 '허쥬마'의 피하주사(SC) 제형인 '허쥬마SC'에 대한 유럽의약품청(EMA) 품목허가를 신청함. 시장 최초 제형으로서 10% 이상의 높은 시장 영향력이 예상됨.

Related Recent Events

View Full Timeline